Filing Flows › Fortress Biotech (FBIO) › Q1 2026 › vs Q1 2025
Fortress Biotech (FBIO) Q1 2026 vs Q1 2025 (year over year)
Fortress Biotech's revenue rose $2.9M (+22%) from $13.1M in Q1 2025 to $16.0M in Q1 2026. The biggest changes: Emrosi +$4.2M (+202%); Foam franchise products (Amzeeq & Zilxi) −$476K (-31%); Other / legacy product revenue −$450K (-62%).
Fortress Biotech, Q1 2026: revenue $16.0M (+22% year over year), operating margin -48.3%, net earnings $137M, operating cash flow $204M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Emrosi | $6.3M | $2.1M | $4.2M | +202% |
| Qbrexza | $5.0M | $5.2M | −$133K | -3% |
| Accutane | $3.3M | $3.7M | −$341K | -9% |
| Foam franchise products (Amzeeq & Zilxi) | $1.1M | $1.5M | −$476K | -31% |
| Other / legacy product revenue | $277K | $727K | −$450K | -62% |
| Revenue | $16.0M | $13.1M | $2.9M | +22% |
| Other income, net | $150M | −$2.4M | $152M | — |
| Costs & expenses | $166M | $37.8M | $128M | +339% |
| Operating costs | $23.8M | $35.5M | −$11.7M | -33% |
| Income tax | $5.1M | $0 | $5.1M | — |
| Net earnings | $137M | −$24.7M | $162M | — |
| Cost of revenue | $6.2M | $4.8M | $1.4M | +30% |
| Research & development | $540K | $3.9M | −$3.4M | -86% |
| SG&A | $15.9M | $25.7M | −$9.8M | -38% |
| Other operating costs | $1.1M | $1.1M | $61K | +6% |
| Operating cash sources | $204M | −$19.6M | $223M | — |
| Depreciation & amortization | $1.2M | $1.2M | $28K | +2% |
| Share-based compensation | $1.8M | $6.3M | −$4.5M | -72% |
| Working capital & other | $63.7M | −$2.4M | $66.1M | — |
| Operating cash flow | $204M | −$19.6M | $223M | — |
Questions
How much did Fortress Biotech's revenue grow year over year in Q1 2026?
Fortress Biotech's revenue rose $2.9M (+22%) from $13.1M in Q1 2025 to $16.0M in Q1 2026.
What drove Fortress Biotech's revenue change in Q1 2026?
Emrosi +$4.2M (+202%); Foam franchise products (Amzeeq & Zilxi) −$476K (-31%); Other / legacy product revenue −$450K (-62%).